Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.
Eli Lilly and Company ( NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago. Its total revenue for the ...
Eli Lilly is experiencing explosive growth thanks ... Mounjaro and Zepbound are still on pace for a record performance in Q4 -- despite falling short of Wall Street's aggressive targets.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE ... are still on pace for a record performance in Q4 -- despite falling short of Wall Street's aggressive ...
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim ...
Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...
The Nasdaq Composite slid more than 3% in Monday’s trading as a slate of AI-related plays, including chip darling Nvidia, ...